替吉奥联合多西他赛对转移性乳腺癌患者血清VEGF、CA72-4水平及生活质量的影响

目的:探讨替吉奥联合多西他赛对转移性乳腺癌(MBC)患者血清血管内皮生长因子(VEGF)、癌抗原72-4(CA72-4)水平及生活质量的影响。方法:选择2015年4月到2016年12月我院收治的90例MBC患者,按乱数表法分为治疗组和对照组,两组均45例。对照组患者给予希罗达联合多西他赛治疗,治疗组患者给予替吉奥联合多西他赛治疗,两组均治疗2个疗程。比较两组患者治疗后的临床疗效和生活质量。比较两组患者治疗前后血清VEGF-A、VEGF-C及CA72-4水平。记录并比较两组患者治疗期间不良反应发生率。结果:治疗组患者的总有效率明显高于对照组(P0.05)。两组患者治疗前血清VEGF-A、VEGF-C、CA72-4水平比较无统计学差异(P0.05);两组患者治疗后血清VEGF-A、VEGF-C、CA72-4水平均明显降低,且治疗组低于对照组(P0.05)。治疗后,治疗组患者的生活质量改善率明显高于对照组(P0.05)。两组患者治疗期间的不良反应发生率比较无统计学差异(P0.05)。结论:替吉奥联合多西他赛治疗MBC临床疗效显著,能够明显改善患者生活质量,降低血清VEGF-A、VEGF-C及CA72-4水平,且安全性较好,值得在临床上推广应用。

Effects of Tegafur Combined with Docetaxel on the Levels of Serum VEGF, CA72-4 and Life Qualities in Patients with Metastatic Breast Cancer

ABSTRACT Objective: To study the effects of tegafur combined with docetaxel on the serum levels of serum VEGF,CA72-4 and life qualities in patients with metastatic breast cancer (MBC). Methods: 90 patients with MBC in our hospital from April 2015 to Decem- ber 2016 were enrolled in this study, and they were divided into the control group and the treatment group according to random number table method, with 45 cases in each group. The control group were treated with xeloda combined with docetaxel, the treatment group were treated with tegafur combined with docetaxel. The patients of two groups were given continuous treatment for 2 courses. The clinical efficacy and life qualities of the two groups after treatment were compared. The serum levels of VEGF-A, VEGF-C, CA72-4 in the two groups before and after treatment were compared, and the incidence of adverse reactions of the two groups during treatment were com- pared. Results: The total effective rate of the treatment group was significantly higher than the control group (P<0.05). There were no sig- nificantly differences in the serum levels of VEGF-A, VEGF-C and CA72-4 in the two groups before treatment (P>0.05). The serum lev- els of VEGF-A, VEGF-C and CA72-4 in the two groups after treatment were significantly lower than before treatment, and the treatment group were significantly lower than the control group (P<0.05). The improvement rate of life qualities in the treatment group after treat- ment was significantly higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The clinical efficacy of tegafur combined with docetaxel in the treatment of MBC is obvi- ous, and it can significantly improve life qualities of patients, reduce the serum levels of VEGF-A, VEGF-C and CA72-4, which is worthy clinical application.